Traction Bronchiectasis: Definition, Pathophysiology, and Clinical Significance

Definition and Pathophysiology

Traction bronchiectasis is the permanent dilation of bronchi caused by the contractile force of surrounding fibrotic lung tissue, which exerts traction and expands the diameter of the involved airways, as described by the American Thoracic Society 1, 2
Traction bronchiectasis occurs when fibrotic lung parenchyma pulls on adjacent bronchi, causing their dilation and distortion, according to the American Journal of Respiratory and Critical Care Medicine 1
It is characterized by irregular bronchial and/or bronchiolar dilatation in areas of pulmonary fibrosis, as noted by the American College of Chest Physicians 3
The contractile forces from surrounding fibrotic tissue create mechanical traction that permanently alters bronchial architecture, as reported in Chest 4

On High-Resolution CT (HRCT) scans, traction bronchiectasis appears as dilated bronchi within areas of fibrotic lung tissue, as described by the American Thoracic Society 1
Key radiological features include enlarged internal bronchial diameter where bronchi appear larger than accompanying arteries (signet ring sign), as noted by the American College of Chest Physicians 5
Irregular bronchial dilatation in a background of reticulation and/or ground-glass attenuation is a characteristic feature, as reported by the American Journal of Respiratory and Critical Care Medicine 3
Dilated bronchi that can be tracked back toward more central bronchi on contiguous HRCT sections are a notable finding, as described by the American College of Chest Physicians 3

Traction bronchiectasis is an important radiological marker in fibrotic lung diseases, particularly in idiopathic pulmonary fibrosis (IPF), as noted by the American Thoracic Society 1, 3
It is also a key feature in fibrotic hypersensitivity pneumonitis, connective tissue disease-associated interstitial lung disease, as reported by the American Journal of Respiratory and Critical Care Medicine 3
The presence and extent of traction bronchiectasis correlate with disease severity and prognosis in patients with interstitial lung abnormalities, although the specific details are not provided in the cited references 1, 3

HRCT scanning is the diagnostic procedure of choice to identify traction bronchiectasis, as recommended by the American College of Chest Physicians 5
Sensitivity and specificity of HRCT for detecting bronchiectasis exceeds 90%, as reported in Chest 5
Identification of traction bronchiectasis on CT scans is associated with moderate interobserver agreement, as noted by the American Journal of Respiratory and Critical Care Medicine 1
In patients with suspected interstitial lung disease, the presence of traction bronchiectasis helps distinguish fibrotic from non-fibrotic patterns, as described by the American Thoracic Society 3

In the context of interstitial lung disease, traction bronchiectasis is a key feature that suggests irreversible fibrosis, as reported by the American Journal of Respiratory and Critical Care Medicine 1
The presence of traction bronchiectasis in a probable UIP pattern on HRCT increases the likelihood of IPF diagnosis, as noted by the American Thoracic Society 3

Traction bronchiectasis serves as a strong independent predictor of mortality in idiopathic pulmonary fibrosis (IPF) 6, 7
Increased extent or severity of traction bronchiectasis defines radiological progression in progressive pulmonary fibrosis (PPF) 6, 8, 7

The American Thoracic Society recommends initiating antifibrotic therapy with either nintedanib or pirfenidone immediately upon diagnosis of IPF or progressive pulmonary fibrosis 8, 9
Both agents slow FVC decline and reduce disease progression 8, 9
The American College of Chest Physicians suggests referring patients with increased risk of mortality for lung transplantation evaluation at diagnosis, not after disease progression 6, 8, 10, 9

Provide supplemental oxygen for hypoxemia (SpO2 <88% at rest or with exertion) 8, 9
Enroll all patients in pulmonary rehabilitation to improve functional capacity and quality of life 8, 9
Involve palliative care early for management of cough, dyspnea, and anxiety 8, 10, 9

Evaluate patients every 3-6 months with pulmonary function tests (FVC and DLCO) 8, 10, 9
Assess symptoms and functional status 8
Monitor oxygen saturation at rest and with exertion 8

For patients with progressive pulmonary fibrosis, apply the same antifibrotic treatment approach (nintedanib or pirfenidone) 6, 8
Monitor for progression using the PPF criteria: worsening symptoms, FVC decline >5%, DLCO decline >10%, or radiological progression including increased traction bronchiectasis 6, 8, 7